SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?


To: aknahow who wrote (808)1/22/2000 11:14:00 AM
From: RWReeves  Respond to of 3158
 
I'd love to see AHP get 'et by P&G. I think the synergies are good. I have liked AHP for close to 20 years and traded in it at times. This would be a great fit and a real boost to both. PFE would I think be a lesser partner. JMO.

RWR



To: aknahow who wrote (808)1/22/2000 4:23:00 PM
From: scaram(o)uche  Read Replies (2) | Respond to of 3158
 
>> Immediate saving of the $2 billion dollar break
up fee. <<

Guffaw. Yes!!

>> Not saying this is wise or good for the development of new drugs. Think many posters will not like the idea and the market apparently thinks it's a bad idea for P & G. <<

I actually think that mega-mergers in pharma are going to be great for the sector. The more these mergers occur, the more levels between the bench scientist and a "yes, go ahead" from management. Now that our companies (read "MLNM et al.") have cash and strong currency, this bureaucratic mess just increases the chances that they can run through this wide hole and break free for a very long run.

And, for a company like P&G, it would get even better..... wandering aimlessly in a field that, while not new to them, is certainly confusing.

This would place ex-Genetics Institute management, now largely heading Wyeth, with significant influence over the direction of research at REGN? Would be a definite plus in terms of guidance/prioritization, but I can't imagine it being construed as an overall positive.